THE INFLUENCE OF RATIONAL COMBINATION THERAPY ON THE QUALITY OF LIFE OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Introduction.Chronic obstructive pulmonary disease (COPD) remains one of the major health problems nowadays. The aim of the research was to increase the treatment efficiency for COPD group B patients by using antibiotics, mucolytics, topical nebulizer therapy and halotherapy sessions in combination therapy. The study enrolled 70 COPD group B patients, the average age of patients was 59.6±2.2 years. The diagnosis was made in accordance with the Order of the Ministry of Public Health of Ukraine as of June 27, 2013 № 555.Patients were divided into two groups. Patients of the first group (control, n=35) received basic therapy - azitrox 500 mg once day, acetylcysteine 200 mg - 2 times daily and combination bronchodilator therapy in the form of dose inhalercontaining fenoterol hydrobromide 50 mcg and ipratropium bromide 20 mcg (berodual H) - 2 times a day, anti-inflammatory therapy in the form of turbuhaler budesonide (pulmicort) 100 mcg twice a day for 7 days. Patients of the second group (main group, n=35) in addition to the basic therapy were prescribed double nebulizer therapy with the compressor nebulizer NEB-10 "Microlife" 2 times a day containing combined broncholytic agent fenoterol hydrobromide with ipratropium bromide (2 Freimid) diluted in 2 ml of saline; solution of budesonide (Pulmicort) nebulized 2 x 0.5 ml mg / mL=1.0 mg, dissolved in 2 ml of saline - 2 times a day №7; and additionally, starting on day 4, halotherapy sessions. Thus, the proposed combined therapy of COPD group B patients is more advanced and rational, it improves the effectiveness of basic medical therapy by optimizing the recovery and rehabilitation process, which has a positive effect on the improvement of the seven components of QOL, it is well tolerated and does not cause side effects.
2. Doskin V.A., Makarova Z.S. Follow-up analysisof the efficiency of halotherapy in the health improvement and rehabilitation of frequently ill children. Russian Journal of Perinatology and Pediatrics. 2014;59 (4):p.80-4.
3. Evidence-based clinical guidelines for Chronic Obstructive Pulmonary Disease. Kiev. The National Academy of medical Sciences of Ukraine, 2019., 113p.
4. Kochetova E.V. SAT test in patients with chronic obstructive pulmonary disease. Tuberculosis and lung disease. 2017;95(12):18-20.
5. Lyzogub V.H., Savchenko O.V., Zapeka Y.S., Baytser M.S. The6-minute walking test in cardiology. "The First Independent Scientific Bulletin" 2015;4:12-16.
6. Nastroga T.V. Optimization of treatment of patients with arterial hypertension in combination with chronic obstructive pulmonary disease in the practice of a family doctor, Nastroga T.V. Family Medicine. 2015;3(59):95-97.
7. Order of the Ministry of Health of Ukraine of June 27, 2013 № 555 "On Approval and Implementation of Medical and Technological Documents on Standardization of Medical Assistance in Chronic Obstructive Pulmonary Disease"р.164
8. Potyazhenko M.M., Ischeykin K.Ye., Nastroga T.V., Sokolyuk N.L., Kitura O.E. Using the rational complex therapy for infectious exacerbation of chronic obstructive pulmonary disease. Medicines of Ukraine. 2016;10(206):79-83.
9. Potyazhenko M.M., Katerenchuk I.P., Nastroga T.V., Nastroga V.S. Rational cytoprotective therapy of coronary heart disease with concomitant chronic obstructive pulmonary disease. The world of medicine and biology. 2016;12,1(55):72-76.
10. Snegirev COPD through the GOLD-2019 prism: topical problems of diagnosis and treatment. Ukrainian Medical Journal. 2019;2;1(130) - III/IV: [HTML] from cyberleninka.ru.
11. Zhdan V.M., Khaymenova G.S., Ivanitsky I.V., Volchenko H.S., Tkachenko M.V. Assessment of the dynamics of clinical and laboratory parameters in the treatment of patients with chronic obstructive pulmonary disease in combination with osteoarthritis. Actual problems of modern medicine. 2017;1;2(58):129-131.
This work is licensed under a Creative Commons Attribution 4.0 International License.